Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The patent portfolio for Allen Davidoff shows 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution is being conducted within 1 distinct art unit, suggesting a specialized focus for the underlying technology. The matter is currently assigned to 1 distinct examiner, centralizing the company's current legal interactions at the USPTO. This narrow scope of activity indicates that the company is currently prioritizing 1 technical disclosure.
ROBINSON, HOPE A is the busiest examiner for this portfolio, with 1 pending office action under review. Since the portfolio is limited to 1 distinct examiner and 1 distinct art unit, the prosecution environment is highly controlled. A practitioner can develop a strategy specifically for ROBINSON, HOPE A, as there are no other examiners or art units influencing the current pending status of the portfolio. This centralized arrangement simplifies the management of the company's intellectual property assets and allows for a focused legal approach.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911789 | METHODS OF TREATING VIRAL INFECTIONS AND HEALTH CONSEQUENCES | ROBINSON, HOPE A | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17911789 | METHODS OF TREATING VIRAL INFECTIONS AND HEALTH CONSEQUENCES | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | — | Pending | Sep 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAllen Davidoff has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hope A Robinson has the most, with 1 of Allen Davidoff's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
